Goldline Pharmaceutical Ltd

Swapan Khandelwal, Promoter and Whole Time Director of Goldline Pharmaceutical Limited, has acquired 60,000 equity shares through an open market purchase. The acquisition took place on June 22, 2026. Prior to this transaction, Khandelwal held 2,749,988 shares, representing 28.65% of the total paid-up capital. After the acquisition, his total holding increased to 2,809,988 shares, which constitutes 29.27% of the company's total paid-up capital. This disclosure is made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Swapan Khandelwal, Promoter and Whole Time Director of Goldline Pharmaceutical Ltd, has acquired 60,000 equity shares, representing 0.62% of the total issued and paid-up share capital. The acquisition was made through open market purchases on June 22, 2026. Following this transaction, Khandelwal's total holding in the company increased to 29.27%. This disclosure is made pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Mr. Swapan Khandelwal, Promoter and Whole Time Director of Goldline Pharmaceutical Ltd, has acquired 60,000 equity shares, representing 0.62% of the total issued and paid-up share capital. The acquisition was made through open market purchases on June 22, 2026. Following this transaction, Mr. Khandelwal's total holding in the company has increased to 29.27%. This disclosure is made pursuant to Regulation 29(2) of SEBI (SAST) Regulations, 2011.

Goldline Pharmaceutical Ltd announced the outcome of its Board Meeting held on June 9, 2026. The board approved the standalone audited financial results for the half-year and full year ended March 31, 2026. Additionally, M/s. Kunal Dutt & Associates were appointed as the Internal Auditor for the company starting from the financial year 2026-27. The financial results will be disseminated on the company's website. The meeting commenced at 4:30 PM and concluded at 5:06 PM.

Goldline Pharmaceutical Ltd has announced the appointment of M/s. Kunal Dutt & Associates as its Internal Auditors, effective from the financial year 2026-27. The decision was approved by the Board of Directors following a recommendation from the Audit Committee. M/s. Kunal Dutt & Associates is a firm of Practicing Company Secretaries known for its expertise in corporate law, compliance, and governance. They are not related to any Director or Key Managerial Personnel of the company. This appointment is a routine corporate governance measure.

Goldline Pharmaceutical Ltd announced the outcome of its Board Meeting held on June 9, 2026. The board approved the standalone audited financial results for the half-year and full year ended March 31, 2026. Additionally, M/s. Kunal Dutt & Associates were appointed as the Internal Auditor for the company starting from the financial year 2026-27. The financial results will be disseminated on the company's website. The meeting commenced at 4:30 PM and concluded at 5:06 PM.

Goldline Pharmaceutical Ltd has announced that its Board of Directors will convene on June 9, 2026. The primary agenda item is to consider and approve the standalone audited financial results for the half-year and full year ended March 31, 2026. The meeting will also address the statement of assets and liabilities. Further details on the outcome will be communicated separately.

Goldline Pharmaceutical Ltd announced the closure of its trading window for designated persons and their immediate relatives from May 19, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and pertains to the consideration of audited financial results for the half year and year ended March 31, 2026. The trading window will remain closed until 48 hours after the declaration of the aforementioned financial results. The date of the board meeting to consider the results will be intimated separately.